What Atrial Fibrillation Is — The Upper Chambers That Lost the Beat, and the Blood That Pools There

The Beat Counted at the Wrist

If you place two fingers on the inside of your wrist, a pulse reaches them at steady intervals. It speeds up when you climb stairs and slows down when you rest, but the intervals are usually even. This article is about a condition where those intervals scatter at random.

It is a common condition. People over the age of 45 face this condition at a rate of roughly one in three to five over their lifetime. The number of people living with this condition worldwide also grew significantly, from 33.5 million in 2010 to 59 million in 2019 (PMID 38362546). This means it is a condition you encounter easily around you.

Many people do not feel this condition. About 10 to 40% of people who have this condition have no symptoms (PMID 39680399). Even if you do not feel it, the danger remains. Even when there are no symptoms, this condition raises the risk of a stroke—which happens when blood going to the brain is blocked—to five times that of someone without this condition (PMID 41117093). And catching it early and treating it on time can lower that risk substantially (PMID 41117093).

We will look in turn at where the beat starts, how we find a symptomless condition, why a scrambled beat leads to stroke, and what we do about it. Unfamiliar terms are explained right where they appear.

Where the Beat Begins

The heart has four chambers. The atria are the two upper chambers, where returning blood is received and held first. The ventricles are the two lower chambers, which squeeze the collected blood out of the heart. The pulse you feel at your wrist is produced every time the ventricles squeeze.

Every time the heart beats, it first generates an electrical signal, and that signal spreads out to make the muscle squeeze. The sinoatrial node is a small cluster of cells that makes the very first electrical signal every time the heart beats. Generating signals on its own is a normal property of these cells (PMID 6310978). This means the place that counts the beat is located right inside the heart. When things are normal, this signal makes the atria squeeze first, and then passes to the ventricles to make them squeeze.

An arrhythmia is a state where the heart beats too fast, too slow, or unevenly. Problems with the beat can happen where the signal is made, where the signal is carried, or a mix of both (PMID 6310978).

Atrial fibrillation is an arrhythmia where the two upper chambers lose their beat and merely quiver rapidly, failing to pump blood out properly. The term "fibrillation" in the name means fine, rapid quivering. It is the most common rapid and irregular arrhythmia, and the subject of this article. Atrial fibrillation happens when electricity scatters wildly across the tissue of the atria (PMID 26226868). Because of rapid and uncoordinated electrical activity, the squeezing power of the atria drops (PMID 22075545).

At the same time, the beat of the entire heart becomes faster and irregular (PMID 22075545). This happens because the scattered signals spill over into the ventricles at uneven intervals. This is why the pulse at the wrist becomes erratic. If this state lasts for a long time, it can tire out the heart muscle (PMID 39893034). Atrial fibrillation is the most common long-lasting arrhythmia, and both new cases and people living with it are increasing in the United States and worldwide (PMID 38033089).

There are multiple factors that trigger atrial fibrillation. Age, high blood pressure, valve disease, heart failure, obesity, smoking, and diabetes all change the structure of the atria bit by bit. Valve disease is a condition where the doors inside the heart that stop blood from flowing backward—meaning the valves—are broken, and heart failure is a state where the heart cannot send as much blood as the body needs. In atria with changed structures, signals pop up in the wrong places instead of the sinoatrial node, or signals frequently get trapped looping around a single spot (PMID 24763464). A 2023 review suggests that most new-onset atrial fibrillation and its consequences stem from modifiable risk factors (PMID 36600003). Therefore, managing risk factors forms the foundation of treatment, as we will see later.

Atrial fibrillation is also classified by how long it lasts. Paroxysmal atrial fibrillation is a pattern where attacks of atrial fibrillation end within 7 days and repeat. If an attack that has started lasts longer than 7 days, it is called persistent, and anything beyond that is called a permanent form.

The 2023 US guideline panel views this disease as a process unfolding in four stages. These are the stage with only risk factors, the stage where changes in the atria are visible on tests but atrial fibrillation is not yet present, the stage with paroxysmal or persistent atrial fibrillation, and the permanent stage (PMID 39680399). In symptomatic paroxysmal atrial fibrillation, slowing down the progression to persistent atrial fibrillation also becomes a goal of treatment (PMID 39680399).

The beat begins at the sinoatrial node, and atrial fibrillation is an arrhythmia where the upper chambers lose that beat and do nothing but quiver.

Those Who Feel It and Those Who Don't

Your chest flutters, you run out of breath, and you tire easily. The symptoms of atrial fibrillation include palpitations, shortness of breath, chest pain, a faint feeling, intolerance to physical exertion, and fatigue (PMID 39680399).

It is sometimes discovered through paths other than symptoms. It is found by chance during a medical visit, by a wrist-worn device, or while checking a heart device planted in the body (PMID 39680399). The latest path is a stroke. According to a 2019 review, 18% of atrial fibrillation cases in the United States first reveal themselves as a stroke, and in these cases, atrial fibrillation is found only after the stroke has struck (PMID 31660316).

An electrocardiogram is a graph that records the flow of electricity generated when the heart beats, using electrodes attached to the body. The diagnosis of atrial fibrillation must be confirmed by an electrocardiogram (PMID 36519436). No matter how clear the symptoms, and no matter what a device tells you, the final verdict is made by the recorded rhythm.

Palpitations are a common complaint in the clinic. The reason the cause is hard to pin down is that symptoms arrive occasionally, sometimes very rarely. Anyone who mainly complains of palpitations goes through a medical interview asking about symptoms in detail, a physical examination, and an electrocardiogram. This alone sometimes yields a plausible diagnosis. Sometimes a few blood tests, a portable electrocardiogram you carry around, and a consultation with a cardiologist are added (PMID 33246525).

Paroxysmal atrial fibrillation makes this recording difficult. This is because an electrocardiogram taken after the seizure has passed leaves behind only a steady rhythm. Atrial fibrillation that passes without symptoms and paroxysmal atrial fibrillation are hard to catch with a physical exam or an electrocardiogram taken once at the hospital. Therefore, the number of people with this disease is easily underestimated (PMID 35328243).

Methods that record for a long time fill this gap. Conventional recording devices commonly used have limits in the amount of record they can hold. Things like patch-type recording devices attached to the body record for multiple days (PMID 33552757).

Symptoms may or may not be present, and the diagnosis is decided by the recorded electrocardiogram.

Should We Look for People Without Symptoms?

These days, wristwatches measure our pulse and notify us when the rhythm is uneven. Thanks to technology packed with wearable devices and diagnostic algorithms, atrial fibrillation is discovered among the general public more often than before (PMID 41794418). Screening is a test that tries to find people who have a disease in advance from among those who have no symptoms. Opinions are divided on atrial fibrillation screening.

The logic of those who want to find it goes like this. A 2017 review states that finding it early and managing it properly cuts the risk of stroke by two-thirds (PMID 28623064). Based on a 2024 review, international guidelines recommend both ways of finding it. These are finding it while someone visits for another reason, and a systematic way where target groups are designated and called in turn. However, the caveat is that more data are needed (PMID 38362546). A 2023 review summarizes the stance of current guidelines like this. Anyone aged 65 or older with even one cardiovascular disease like high blood pressure can have systematic screening justified (PMID 36519436).

Most blood pressure monitors contain a detection algorithm that identifies atrial fibrillation. This algorithm correctly identifies people with atrial fibrillation as having it (sensitivity) 96% of the time, and correctly identifies people without it as not having it (specificity) 94% of the time. Even so, an electrocardiogram is required to confirm a diagnosis (PMID 36519436). Regarding smartwatches, a 2019 review considers that this technology is unlikely to become the final diagnostic tool. Rather, it serves as a starting point that prompts a person who receives an uneven rhythm notification to seek medical care for confirmation (PMID 31660316).

The logic on the other side goes like this. A 2021 clinical review notes that there is no evidence that finding atrial fibrillation in people without symptoms improves the actual outcomes patients experience (PMID 33851396).

A 2025 review lists benefits and worries together. The benefits are the possibility of finding symptomless atrial fibrillation early and treating it in time to reduce strokes. Important worries include false positives, inconclusive results, unnecessary additional tests, patient anxiety, and the burden on medical resources. False positives are results that say a disease is present when it is not. This review considers that the value of screening overall depends on the balance between the benefit of finding it better and overdiagnosis, psychological burden, and cost (PMID 41117093). Overdiagnosis is finding and diagnosing a disease that would have passed without trouble if it had not been found.

It is not yet known whether the atrial fibrillation found all carries the same weight. A 2022 review notes that it is not yet established whether the atrial fibrillation found by devices all carries the same risk. Short and infrequent episodes may not gain the benefit of blood-thinning medication (PMID 36136225). A 2017 review views it differently depending on who it was found in. Symptomless atrial fibrillation found in a person who has not experienced a stroke is seen as a basis to record and watch rather than use medication right away. If it was found in a person who recently experienced an unknown-cause stroke, blood-thinning treatment is considered necessary (PMID 27756556).

Treatment after finding it also hangs in the balance. A randomized trial is a study that divides participants like a draw, applies the treatment to be tested to only one side, and compares the results of the two sides. There is an analysis combining two randomized trials (2,536 people, 4,012 people) targeting patients with atrial fibrillation found by implanted body devices. Oral blood-thinning medication reduced strokes caused by blocked cerebrovessels to 0.68 times compared to drugs like aspirin or no treatment. Instead, major bleeding increased by 1.62 times, and cardiovascular death and all-cause death were not reduced (PMID 37952187). For these patients found by devices, this means they paid the price of bleeding in exchange for preventing stroke, and there was no evidence that people losing their lives was reduced.

Finding symptomless atrial fibrillation comes with both the opportunity to prevent stroke and the burden of false alarms and overdiagnosis, and what is found changes the balance that follows.

Blood Pools in the Trembling Room

The risk of a person with atrial fibrillation experiencing a stroke goes up by roughly five times (PMID 36537565).

The first step of that pathway is blood pooling. If the atria cannot squeeze and only tremble, the blood inside them fails to exit on time and lingers. Atrial fibrillation pools blood inside the atria in this way, and the pooled blood can solidify into a mass. When this mass floats away to another part of the body and blocks a vessel, a stroke occurs (PMID 33552757).

There is a spot where masses form primarily. The left atrial appendage is a small space protruding like a pouch from the left atrial wall. Because it is a pouch with a closed end, it is a place where blood tends to linger longer. Most blood clots in patients with atrial fibrillation form in this pouch (PMID 37685589), and this pouch is counted as the main starting point from which blood clots float away (PMID 39027946).

An embolus is a mass created elsewhere that rides along a blood vessel, floats away, and gets caught in a narrow place. In atrial fibrillation, blood pooled in the left atrium solidifies, and that mass floats away to the brain and causes a stroke (PMID 33516402). Blood in the left atrium passes through the left ventricle and goes straight out into arteries heading to the entire body. Arteries heading to the brain branch off along that path. A cerebral infarction is a stroke in which an artery going to the brain is blocked, and the brain tissue ahead of it dies without receiving oxygen.

A stroke generated through this pathway is heavy. A stroke caused by atrial fibrillation more often leads to loss of life or leaves severe disability (PMID 36537565). Twenty to 25% of cerebral infarctions are due to masses floating down from the heart, and atrial fibrillation is their most common cause. It is estimated that 15% of all strokes worldwide are due to atrial fibrillation (PMID 34890796).

Some people have their atrial fibrillation revealed only after experiencing a stroke. A meta-analysis is an analysis that gathers the results of multiple studies dealing with the same question and recalculates them together. In a meta-analysis gathering 50 studies encompassing over 10,000 patients who recently experienced a stroke, new atrial fibrillation was discovered in 7.7% through an electrocardiogram taken at the time of admission. Another 16.9% were diagnosed during hospitalization and for 3 weeks after discharge, making 23.7% in total (PMID 27756556). This means more people were found later than those found by the electrocardiogram taken at admission. This is why atrial fibrillation is persistently searched for in people who have experienced a stroke.

There are parts of this pathway that are still unknown. A 2023 review notes that the mechanism of blood clot formation connecting atrial fibrillation and stroke is not well elucidated (PMID 36537565). A 2017 review considers that changes in atrial tissue that readily form blood clots can cause emboli even without atrial fibrillation (PMID 28154101). And a 2015 review notes that the stroke risk of all atrial fibrillation patients must be evaluated even after normal rhythm is regained (PMID 26226868).

Risks that go along with atrial fibrillation extend beyond stroke. There is a meta-analysis gathering 104 cohort studies and 9,686,513 participants (including 587,867 atrial fibrillation patients among them). A cohort study is a study that watches a group of people over a long time to see who develops which disease. In this analysis, people with atrial fibrillation had a 2.42-fold stroke risk, a 1.46-fold risk of all-cause mortality, and a 4.99-fold heart failure risk compared to those without. When looking at the increased magnitude as absolute risk—which calculates it by the number of people who actually experience the disease—heart failure increased the most. The authors conclude that measures to reduce outcomes beyond stroke are also needed (PMID 27599725).

The multiple for stroke risk varies by study, sometimes being written as three to five times (PMID 34890796). The fivefold increase seen earlier and the value from this meta-analysis also came from different studies.

If blood pooled in a trembling room solidifies, floats away, and blocks a brain artery, it is a cerebral infarction, and that mass mostly forms in the left atrial appendage.

Preventing Stroke

Major guidelines all view caring for three things together as the core of atrial fibrillation management. These are stroke prevention, symptom relief, and the identification and management of risk factors (PMID 41794418). The 2024 European guidelines organized this into four pillars. These are the management of co-occurring other diseases (comorbidities) and risk factors, stroke prevention, symptom relief, and periodic reassessment (PMID 39716733).

The tool for stroke prevention is medication that prevents blood clots from forming. Anticoagulant therapy is a treatment that lowers the blood's clotting power with medication to keep clots from forming. There are patients whose stroke risk is estimated to be 2% or more per year, meaning more than two out of a hundred people in a single year. In such patients, anticoagulant therapy reduces the risk of stroke by 60 to 80% compared to a dummy pill. A 2025 review article summarizes that oral anticoagulants are recommended for these patients. For most patients, newer oral anticoagulants are recommended over older drugs used for a long time. This is because the risk of bleeding is lower (PMID 39680399).

The price paid is bleeding. Bleeding caused by long-standing anticoagulants is a major reason for hospital admission due to drug side effects (PMID 28279251). Therefore, whom to use them for is decided on a case-by-case basis. The 2018 American College of Chest Physicians guidelines view stroke risk as varying from person to person. They state that it changes depending on whether one has risk factors such as heart failure, high blood pressure, age, diabetes, and a prior stroke.

These guidelines divide judgments based on risk factors. They suggest that antithrombotic therapy not be used for people at low risk. Antithrombotic therapy broadly refers to drugs that block blood clots, such as anticoagulants and drugs like aspirin. If there is one risk factor other than sex, they suggest oral anticoagulant therapy, and if risk is high with two or more, they recommend it. In the language of the guidelines, a "suggestion" is a step weaker an expression than a "recommendation." In risk scores, being female also counts as one, but it is left out and not counted in this judgment. The conclusion of the guidelines is that if there is even one risk factor, oral anticoagulant therapy is the most appropriate choice. The same guidelines note that modifiable bleeding risk factors, such as uncontrolled blood pressure and heavy drinking, should be checked at every clinic visit (PMID 30144419).

There is benefit, but they are underused. A significant proportion of patients who need anticoagulant therapy either do not receive treatment or stop soon after starting. A 2024 international consensus document notes that this situation has not improved sufficiently even after the introduction of new drugs with less bleeding (PMID 38291925). A 2026 scientific statement from the American Heart Association also considers that new oral anticoagulants are still underused (PMID 42377292).

There is also a method for people who find it difficult to maintain anticoagulant therapy for a long time. Left atrial appendage closure is a procedure in which a thin tube is guided along blood vessels to implant a device that blocks the opening of the left atrial appendage. It is a method of closing the opening of the pouch where blood clots mainly form. This procedure is mainly used for stroke prevention in people who cannot use anticoagulants for a long time (PMID 40754231).

There is an analysis tracking 3,116 patients across 4 randomized trials for 36 to 49.6 months. Left atrial appendage closure showed no difference in stroke or systemic embolism compared to oral anticoagulants. Systemic embolism is an event where a clot blocks an artery in the body other than the brain. All-cause mortality was 0.78 times, and hemorrhagic stroke caused by a burst blood vessel in the brain was 0.34 times. There was no difference in major bleeding, including bleeding during the procedure. The authors conclude that it can be considered as an alternative to anticoagulants in some selected patients (PMID 40754231). Most randomized trials to date have compared it with older anticoagulants, and trials comparing it with newer drugs are underway (PMID 39027946).

Anticoagulant therapy greatly reduces strokes, but it must be weighed against bleeding, and for those who cannot maintain that treatment for long, there is a procedure that blocks the opening.

Managing Rhythm

Rhythm comes in two paths. Rate control is a treatment that leaves atrial fibrillation alone and only slows down the speed at which the lower chambers beat. It is known as a safe and effective strategy for patients without symptoms (PMID 37969851). Rhythm control is a treatment to bring back the normal rhythm led by the sinus node and keep that rhythm. Drugs, electrical shocks, and procedures fall under this (PMID 38727662).

The results of comparing the two paths have differed across eras. A systematic review is an article that gathers and organizes related studies without omission using a set method. In a 2014 systematic review that gathered 162 studies and 28,836 patients, the two strategies were compared using drugs. Mainly in older patients with mild symptoms, the two strategies showed similar effects on death and stroke (PMID 24887617).

When you gather up to recent trials, the picture changes. There is a 2024 meta-analysis that gathered 18 randomized trials and 17,536 patients. Rhythm control reduced cardiovascular death to 0.78 times, stroke to 0.80 times, and heart failure hospitalization to 0.80 times compared to rate control. All-cause death was 0.86 times, but it was hard to say it decreased. This is because the 95% confidence interval, which is the range where the true value is likely to lie, was 0.73 to 1.02, straddling 1, which means "no difference".

These gains came from recent studies. The more procedural ablation was used on the rhythm control side, the better the results minus stroke. The authors conclude that recent methods of rhythm control reduce cardiovascular death, heart failure events, and stroke (PMID 38727662).

The timing of starting is also a question. There is a trial where early-started rhythm control in atrial fibrillation at the early stage of diagnosis reduced bad cardiovascular outcomes. The targets were patients over 75 years old, or with a stroke risk score of 2 or higher and cardiovascular disease. A 2023 review dealing with hypertension introduces this trial (PMID 36519436). The stroke risk score is a value obtained by scoring and adding up the risk factors seen earlier.

A 2024 review welcomes this trend, yet considers it still premature to recommend early rhythm control to all atrial fibrillation patients. It states that questions remain starting from how to define "early" and "successful" (PMID 37054762). A 2026 review suggests dealing with newly onset atrial fibrillation more aggressively. At the same time, it writes that robust evidence for that timing is lacking, and there is a delicate balance between the benefit of preventing stroke and progression and the complications of treatment (PMID 40873195).

The procedure for rhythm control started from one discovery. It is that the erratic signals fueling atrial fibrillation start in the veins returning from the lungs to the heart. Catheter ablation is a procedure where a thin tube is inserted along blood vessels all the way into the heart, and tissue at the site where erratic signals start or pass is intentionally damaged to block those signals from spreading. Among those, the method of electrically isolating the vein entrances has become the most widely used (PMID 39322413).

In the 2014 systematic review, evidence that the vein isolation procedure is better than drugs in reducing recurrence in relatively young patients with paroxysmal atrial fibrillation was strong (PMID 24887617). A 2025 review organizes this procedure as the first-line treatment—meaning the treatment considered first—in symptomatic paroxysmal atrial fibrillation. This is to reduce symptoms and slow progression to persistent (PMID 39680399). The 2024 European guidelines also place it as the first rhythm control choice in suitable paroxysmal patients (PMID 39716733).

The effect on stroke is split by timing. In a 2025 meta-analysis gathering randomized trials, catheter ablation reduced cerebral infarction after 30 days to 0.63 times compared to medical treatment. Death was reduced to 0.73 times, and heart failure hospitalization to 0.68 times. Instead, cerebral infarction within 30 days after the procedure increased to 6.81 times. Therefore, total cerebral infarction combining the periods was 0.77 times (95% confidence interval 0.55 to 1.09), making it uncertain whether it decreased. The authors note as limitations differences between trials and the fact that trials not distinguishing who received what treatment were mixed (PMID 40587868). This means cerebral infarction increases right after the procedure and decreases thereafter, so the combined effect is hard to state yet.

Whichever path you choose, there is something decided separately. A 2007 review writes that what to use as treatment to prevent stroke is decided according to the person's stroke risk, regardless of whether it is rate control or rhythm control (PMID 17309423). This means the judgment of stroke prevention does not automatically disappear just because the rhythm was brought back.

The foundation of every step is risk factors. A 2021 systematic review summarizes for each risk factor like this. Controlling blood pressure reduces newly developing atrial fibrillation and recurrence. Treating sleep apnea, where the airway is blocked during sleep, reduces episodes. Alcohol raises risk in proportion to the amount drunk, and quitting reduces the risk of recurrence.

Exercise stands on the risk side if it is too little or too much. Both sitting for a long time and doing high-intensity endurance exercise for a long time are risk factors, and moderate exercise is associated with lower risk. In overweight or obese people, losing 10% or more of body weight has a relationship where the risk is lowered. The authors conclude that lifestyle and risk factor management are very effective in preventing atrial fibrillation (PMID 34583808).

Patients who managed risk factors across the board had greater reductions in symptoms and the time occupied by atrial fibrillation, and more ablation successes (PMID 31712316). Lifestyle and risk factor management, including weight loss and exercise, are recommended for all four stages seen earlier, from the stage with only risk factors to the permanent stage (PMID 39680399).

Rhythm either slows the speed or returns it to normal, stroke prevention is decided separately either way, and risk factor management is always kept at the foundation.

From a Wrist Alert to a Decision

Let's follow one person. A sixty-eight-year-old person with high blood pressure receives an alert on their wrist watch in the evening that the rhythm is irregular. They felt neither palpitations nor shortness of breath. As seen earlier, about 10 to 40 percent of people with atrial fibrillation have no symptoms (PMID 39680399).

As a 2019 review states, this alert is a starting point leading to a visit for confirmation (PMID 31660316). The alert might be wrong. False positives and the subsequent additional tests and anxiety are counted as the price of screening (PMID 41117093).

At the clinic, an electrocardiogram is taken. A single electrocardiogram can come back normal. This is because paroxysmal atrial fibrillation is hard to catch with a single electrocardiogram (PMID 35328243). A device worn on the body to record for multiple days fills this gap (PMID 33552757). When atrial fibrillation is caught on a multi-day electrocardiogram, the diagnosis is confirmed then (PMID 36519436).

The next question is stroke. Age and high blood pressure fall under risk factors that gauge stroke risk (PMID 30144419). In patients whose risk is estimated at 2 percent or more per year, anticoagulant treatment reduces stroke by 60 to 80 percent compared to a placebo, and a 2025 review summarizes that oral anticoagulants are recommended for such patients (PMID 39680399).

However, this person's atrial fibrillation was found by a device without symptoms. As seen earlier, it has not yet been settled whether short and rare episodes yield the same benefit (PMID 36136225). Whether to start medication is determined by assessing the person's risk separately (PMID 39716733). On the other side is bleeding. This person's blood pressure appears here once more. Uncontrolled blood pressure is also a bleeding risk factor that must be checked at every visit (PMID 30144419).

The decision about the rhythm is also separate. For patients without symptoms, rate control is a safe and effective strategy (PMID 37969851). There are trials where early rhythm control was helpful, but there is also a judgment that it is premature to recommend it to all patients (PMID 37054762). And blood pressure control is also effective in reducing the recurrence of atrial fibrillation (PMID 34583808). A single blood pressure touches both stroke risk, bleeding risk, and atrial fibrillation itself.

These decisions are re-evaluated each time (PMID 39716733). A 2026 review concludes that patient-centered care and better health literacy can enable patients to take a more active role in managing their own atrial fibrillation (PMID 41794418).

The alert is the starting point, the electrocardiogram makes the confirmation, and behind it come the scale of stroke and bleeding, the choice about the rhythm, and risk factor management in turn.

Where to Look Next

The four chambers of the heart, the paths blood travels, and where the left atrium sits along those paths are covered in How the Heart Moves Blood — Four Chambers, Four Doors, Two Loops. Blood pressure—which ties together atrial fibrillation, stroke, and bleeding—is examined in What Blood Pressure Measures — Two Numbers, and an Answer That Changes With Where You Measure, and the disease that narrows the road feeding blood to the heart muscle is looked at in What Coronary Artery Disease Is — The Road That Feeds the Heart, Narrowed and Blocked.

What a drifted lump causes in the brain, and why time dictates the outcome there, leads straight into the next article, What a Stroke Actually Is — Blocked, Burst, and the Clock.

When a detection algorithm with 96% sensitivity and 94% specificity announces "atrial fibrillation," the actual probability that it is atrial fibrillation depends on who the person receiving the alert is. That calculation is handled in What a Test Actually Tells You — An Introduction to Sensitivity, Specificity, and Pretest Probability. How numbers like "0.68 times" or "reduced by 60–80%" translate into stories of real people is answered in What Does "50% Lower Risk" Mean in People? — Reading Relative Risk, Absolute Risk, and NNT.

The pros and cons surrounding screening, and the gains and losses of early rhythm control, are debates that each need a separate piece, and they have not been written yet.

Source Papers

• "Atrial fibrillation: epidemiology, screening and digital health." (2024) — PMID 38362546 — Lifetime risk after age 45 is 1 in 3 to 1 in 5. Global prevalent cases grew from 33.5 million in 2010 to 59 million in 2019. International guidelines recommend opportunistic or systematic screening, but more data are needed.
• "Atrial Fibrillation: A Review." (2025) — PMID 39680399 — Symptoms include palpitations, shortness of breath, chest pain, presyncope, exercise intolerance, and fatigue; 10% to 40% are asymptomatic. The 2023 US guidelines define 4 stages (paroxysmal ≤7 days, persistent >7 days, permanent). Anticoagulation reduces stroke by 60% to 80% in those with a risk of >2% per year, favoring newer non-vitamin K antagonist oral anticoagulants due to lower bleeding. Early rhythm control is indicated for some patients, and catheter ablation is first-line therapy for symptomatic paroxysmal cases to suppress progression. Lifestyle and risk factor management should be applied to all stages.
• "Atrial Fibrillation Screening: Burden or Benefit for Patients and the Healthcare System." (2025) — PMID 41117093 — Even without symptoms, the risk of ischemic stroke is 5 times higher. The benefits of screening—early diagnosis, treatment, and potential reduction in stroke—must be weighed against burdens such as false positives, inconclusive findings, unnecessary tests, anxiety, and resource utilization. The value depends on balancing overdiagnosis, psychological burden, and cost.
• "Pathophysiologic mechanisms of cardiac arrhythmias." (1983) — PMID 6310978 — Arrhythmias stem from abnormalities in impulse generation, conduction, or a combination of both. Automaticity is a normal property of cardiac cells such as the sinoatrial node.
• "Atrial Fibrillation." (2015) — PMID 26226868 — Atrial fibrillation is a supraventricular tachyarrhythmia caused by chaotic depolarization of atrial tissue. Even after normal rhythm is restored, embolic risk must be assessed in all patients.
• "Atrial fibrillation (chronic)." (2011) — PMID 22075545 — Rapid and uncoordinated atrial activation impairs the mechanical function of the atria.
• "Atrial Fibrillation-Induced Cardiomyopathy." (2025) — PMID 39893034 — Elements of atrial fibrillation-induced cardiomyopathy include tachycardia, irregular beating, and atrial myopathy. Atrial fibrillation and heart failure share a bidirectional relationship.
• "2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation." (2024) — PMID 38033089 — Atrial fibrillation is the most common sustained arrhythmia, and its incidence and prevalence are rising in the US and globally.
• "The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features, epidemiology, and mechanisms." (2014) — PMID 24763464 — Age, hypertension, valvular heart disease, heart failure, obesity, smoking, and diabetes drive structural remodeling, which in turn promotes ectopic firing and reentry.
• "Epidemiology and modifiable risk factors for atrial fibrillation." (2023) — PMID 36600003 — New atrial fibrillation and its consequences originate largely from modifiable lifestyle risk factors. Approximately 60 million people are affected globally.
• "Apple Watch, Wearables, and Heart Rhythm: where do we stand?" (2019) — PMID 31660316 — In the US, 18% of atrial fibrillation cases first present as a stroke. Repeated short electrocardiogram recordings identify 4 times more patients than a single recording. Wearable devices serve less as definitive diagnostic tools than as a starting point for confirmatory evaluation following an irregular rhythm notification.
• "Evidence-Based Approach to Palpitations." (2021) — PMID 33246525 — Palpitations are intermittent, making their underlying cause difficult to diagnose. All evaluations involve a medical history, physical examination, electrocardiogram, and sometimes limited testing, ambulatory monitoring, or specialist referral.
• "Atrial Fibrillation Detection and Management in Hypertension." (2023) — PMID 36519436 — Blood pressure monitor algorithms show 96% sensitivity and 94% specificity, but confirmation via electrocardiogram is required for diagnosis. Current guidelines suggest that systematic screening may be justified in individuals aged 65 and older with one or more cardiovascular diseases. In the EAST-AFNET 4 trial, early rhythm control for recent-onset atrial fibrillation reduced adverse cardiovascular outcomes.
• "Current Advancement in Diagnosing Atrial Fibrillation by Utilizing Wearable Devices and Artificial Intelligence: A Review Study." (2022) — PMID 35328243 — Asymptomatic and paroxysmal atrial fibrillation are difficult to catch with physical examination or a 12-lead electrocardiogram, leading to an underestimation of its prevalence.
• "Newer Diagnostic and Cost-Effective Ways to Identify Asymptomatic Atrial Fibrillation for the Prevention of Stroke." (2021) — PMID 33552757 — Atrial fibrillation creates blood stasis within the atrium, forming thrombi that increase the risk of systemic embolism and stroke. Holter monitors offer short recording durations, whereas patch-type and loop recorders capture data over longer periods.
• "Atrial fibrillation." (2026) — PMID 41794418 — Wearable devices are increasing detection in the general population. Major guidelines emphasize integrated care encompassing stroke prevention, symptom relief, and risk factor management. Patient-centered care and health literacy help patients play an active role.
• "To Screen or Not to Screen? Examining the Arguments Against Screening for Atrial Fibrillation." (2017) — PMID 28623064 — Approximately 40% of cases are asymptomatic. Early detection and appropriate management reduce stroke risk by two-thirds. Arguments against screening are evaluated against World Health Organization criteria.
• "Atrial Fibrillation and Ischemic Stroke: A Clinical Review." (2021) — PMID 33851396 — Stroke risk is 5 times higher and mortality is doubled. There is no evidence that screening asymptomatic individuals improves clinical outcomes.
• "Stroke Prevention in Atrial Fibrillation." (2022) — PMID 36136225 — It remains uncertain whether device-detected atrial fibrillation carries the same risk across all cases, and short, infrequent episodes may not confer a benefit from anticoagulation.
• "Silent Atrial Fibrillation and Cryptogenic Strokes." (2017) — PMID 27756556 — Across 50 studies involving roughly 10,000 recent stroke patients: admission electrocardiography detected 7.7%, an additional 16.9% were found within 3 weeks, totaling 23.7%. In roughly 10,000 pacemaker patients followed for 24 months: 43% experienced atrial fibrillation lasting longer than 5 minutes on at least one day, with an annual stroke rate of 0.23%.
• "Direct Oral Anticoagulants for Stroke Prevention in Patients With Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials." (2024) — PMID 37952187 — Two randomized trials (2,536 and 4,012 participants). Anticoagulation yielded a relative risk of 0.68 for ischemic stroke and 1.62 for major bleeding. There was no reduction in cardiovascular mortality or all-cause mortality.
• "Atrial fibrillation and stroke." (2023) — PMID 36537565 — Stroke risk is 5 times higher. Strokes related to atrial fibrillation are more frequently fatal or severely disabling. The thrombotic mechanisms linking the two are not yet fully elucidated.
• "Non-Pharmacological Stroke Prevention in Atrial Fibrillation." (2023) — PMID 37685589 — Most thrombi originate in the left atrial appendage, and because anticoagulants carry side effects and contraindications, left atrial appendage closure has emerged as a non-pharmacological alternative.
• "Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives." (2024) — PMID 39027946 — The left atrial appendage is the primary source of embolism. Most randomized studies have compared closure against vitamin K antagonists, and comparative trials with newer drugs are ongoing.
• "Atrial Fibrillation and Stroke." (2021) — PMID 33516402 — Blood stasis in the left atrium and subsequent embolism to the brain increase stroke risk. Oral anticoagulation reduces stroke by roughly 64%.
• "Atrial fibrillation and stroke: A review and new insights." (2023) — PMID 34890796 — Cardioembolic events account for 20% to 25% of ischemic strokes, with atrial fibrillation being the most common cause. Atrial fibrillation is estimated to account for 15% of all strokes globally.
• "Atrial fibrillation." (2007) — PMID 17309423 — Rhythm-control drugs have a 1-year success rate of 40% to 60% and significant side effects. Antithrombotic selection is guided by stroke risk regardless of whether a rate or rhythm strategy is chosen. Stroke rates are similar across paroxysmal, persistent, and permanent types.
• "Cardioembolic Stroke." (2017) — PMID 28154101 — A thrombogenic atrial substrate can cause atrial embolism even in the absence of atrial fibrillation (atrial cardiomyopathy).
• "Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis." (2016) — PMID 27599725 — 104 cohort studies involving 9,686,513 participants (587,867 with atrial fibrillation). Relative risk for stroke was 2.42, all-cause mortality 1.46, and heart failure 4.99 (the largest absolute increase). The authors concluded that interventions addressing outcomes beyond stroke are needed.
• "Spotlight on the 2024 ESC/EACTS management of atrial fibrillation guidelines: 10 novel key aspects." (2024) — PMID 39716733 — The AF-CARE pillars comprise comorbidities and risk factors, stroke prevention, symptom relief, and reevaluation. Catheter ablation is a first-line rhythm-control option for paroxysmal cases.
• "Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation…" (2017) — PMID 28279251 — Bleeding complications from long-established anticoagulants are a major cause of drug-related hospital admissions.
• "Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report." (2018) — PMID 30144419 — Stroke risk varies heterogeneously depending on risk factors. No antithrombotic therapy is suggested for low-risk individuals, whereas anticoagulation is considered if there is one or more non-sex risk factor. Modifiable bleeding risk factors, such as uncontrolled blood pressure or heavy alcohol intake, should be reviewed at every visit.
• "Practical guide on left atrial appendage closure for the non-implanting physician: an international consensus paper." (2024) — PMID 38291925 — A significant proportion of patients who require anticoagulation either do not receive treatment or discontinue it shortly thereafter, a gap that has not been fully resolved by the advent of newer drugs. Left atrial appendage closure is performed primarily via catheter-based device insertion.
• "Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement." (2026) — PMID 42377292 — Despite strong evidence, newer non-vitamin K antagonist oral anticoagulants remain underprescribed and sometimes inappropriately used.
• "Left atrial appendage closure vs oral anticoagulation for stroke prevention in atrial fibrillation: Long-term outcomes from 4 randomized trials." (2025) — PMID 40754231 — 4 randomized trials involving 3,116 participants followed for 36 to 49.6 months. There was no difference in stroke or systemic embolism, but all-cause mortality relative risk was 0.78 and hemorrhagic stroke relative risk was 0.34. Mainly used in patients with contraindications to long-term anticoagulation, the authors concluded it may be considered as an alternative in selected patients.
• "Atrial Fibrillation: Rate Versus Rhythm Control." (2023) — PMID 37969851 — Rate control governs ventricular response and is safe and effective for asymptomatic patients. Comparison of mortality benefits remains unclear.
• "Rhythm vs Rate Control Strategy for Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials." (2024) — PMID 38727662 — 18 randomized trials involving 17,536 participants. Rhythm control reduced cardiovascular mortality (hazard ratio 0.78), stroke (0.80), heart failure hospitalization (0.80), and all-cause mortality (0.86, confidence interval 0.73–1.02). Benefits were greater in recent studies and improved with higher rates of ablation (except for stroke).
• "Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review." (2014) — PMID 24887617 — 162 studies involving 28,836 participants. Pharmacological rate and rhythm strategies yielded similar mortality and stroke outcomes, primarily in older adults with mild symptoms. Pulmonary vein isolation was superior to drugs in reducing recurrence among younger patients with paroxysmal atrial fibrillation.
• "Benefits of early rhythm control of atrial fibrillation." (2024) — PMID 37054762 — In EAST-AFNET 4, early rhythm control at the time of diagnosis reduced adverse outcomes with few complications. However, it is premature to recommend early rhythm control for all patients, and definitions of "early" and "successful" remain debated.
• "Recent-onset atrial fibrillation: challenges and opportunities." (2026) — PMID 40873195 — Aggressive management is suggested for newly onset atrial fibrillation, though robust evidence is lacking, and a delicate balance exists between benefits and complications.
• "Catheter ablation for atrial fibrillation: indications and future perspective." (2024) — PMID 39322413 — Pulmonary veins were first identified as the origin of ectopic trigger signals, making pulmonary vein isolation the most widely used procedure.
• "Catheter and Surgical Ablation for Atrial Fibrillation: A Systematic Review and Meta-analysis." (2025) — PMID 40587868 — Compared to medical therapy, catheter ablation reduced 30-day ischemic stroke relative risk to 0.63, mortality to 0.73, and heart failure hospitalization to 0.68. Ischemic stroke within 30 days had a relative risk of 6.81, yielding an overall ischemic stroke relative risk of 0.77 (0.55–1.09). Limitations include heterogeneity and lack of blinding.
• "Prevention and Treatment of Atrial Fibrillation via Risk Factor Modification." (2021) — PMID 34583808 — Blood pressure control prevents onset and recurrence, treatment of sleep apnea reduces episodes, alcohol consumption shows a dose-dependent relationship with abstinence reducing recurrence, a sedentary lifestyle and long-term high-intensity endurance exercise increase risk, whereas moderate exercise lowers risk. In overweight and obese individuals, a weight loss of 10% or more is associated with lower risk.
• "Lifestyle modifications for treatment of atrial fibrillation." (2020) — PMID 31712316 — Risk factor management constitutes the fourth pillar. Patients managed comprehensively experienced greater reductions in symptoms and atrial fibrillation burden, alongside higher procedural success rates with ablation.